#United States #St. Petersburg #Cell Therapy #CaseBioscience #CaseCryo

Overview of CaseBioscience's Latest Innovations

CaseBioscience® has made a significant leap in the realm of biopreservation solutions with the unveiling of CaseCryo® CTG DMSO and CaseStor® HSS Hypothermic Storage Solution during the Advanced Therapies Week (ATW) 2026 event in St. Petersburg, Florida. These cutting-edge products are engineered specifically for cell therapy applications, aiming to enhance the quality and effectiveness of crucial cell preservation processes.

Innovative Solutions for Cell Preservation

The CaseCryo® CTG DMSO is positioned as a next-generation cryopreservation solution. Designed for the rigorous demands of clinical cell therapy development, this product leverages state-of-the-art technology to ensure improved long-term recovery and expansion of T cells and human pluripotent stem cells (hPSCs). Manufacturered under stringent guidelines that align with cGMP and ISO 13485:2016 certifications, CaseCryo® DMSO reflects CaseBioscience’s commitment to integrating high-quality standards into their production processes.

In parallel, the CaseStor® HSS solution provides a controlled environment for hypothermic storage of cells and tissues. Its design facilitates better post-storage expansion of various cell types, including hPSCs, T cells, and mesenchymal stem cells (MSCs). With both solutions, CaseBioscience aims to address the common challenges faced in cell therapy workflows, promoting sustained cell function and survivability.

Regulatory Compliance and Clinical Relevance

The introduction of these products goes beyond mere innovation; it reflects the company's strategy to maintain regulatory compliance in a highly regulated industry. Drug Master Files (DMFs) have been filed for both solutions to assist with clinical development and align with necessary regulatory frameworks, ensuring that they meet the requirements needed for clinical applications.

Kevin Flynn, PhD, Chief Scientific Officer of CaseBioscience, emphasized the importance of these products in enhancing the viability and performance of cell therapies: “Cryopreservation and hypothermic storage are critical to enabling cell and tissue therapies. With CaseCryo® CTG DMSO and CaseStor® HSS, we're providing solutions that prioritize long-term cell performance and regulatory rigor.”

Expanding the Biopreservation Portfolio

These new product launches are an important addition to CaseBioscience’s existing portfolio of biopreservation solutions, which already includes CaseCryo® DMSO, CaseCryo® NON-DMSO, CaseBase® Washing Medium, and CaseBase® Dissociation Medium. The expansion signals an ongoing commitment to advancing the field of cell therapy with innovative products that align with the latest research and development in biotechnology.

Additional formulations are currently in development, such as CaseCryo® CTG NON-DMSO, which reflects a continuous effort to explore alternative cryoprotectants for clinical applications. This development trend is set against the backdrop of CaseBioscience’s commitment to research-led innovation, which was recently highlighted at the ISSCR PSC-Derived Therapies Symposium.

Conclusion

As the field of cell therapy continues to evolve, solutions like CaseCryo® CTG DMSO and CaseStor® HSS play pivotal roles in shaping how cells and tissues are preserved and utilized in clinical settings. The ongoing commitment by CaseBioscience to research-driven biopreservation reflects a vision for not only supporting innovations in cell therapy but also ensuring the highest standards of quality and regulatory compliance, setting a benchmark for the industry. For further details about these newly launched products, interested parties can visit CaseBioscience's website or connect with their representatives at ATW 2026.